Companion Diagnostics Conference London

Partnering, not footfall

Companion diagnostics conference London: where co-development starts

Most companion diagnostic deals begin with a pharma team asking who can build, validate and secure approval for an assay alongside its drug, and ImmunoMark Summit is the companion diagnostics conference London pharma CDx teams use to have that conversation early.

CDx partners are not chosen at a booth. They are chosen by small groups in precision medicine, translational science, regulatory affairs and medical diagnostics, usually well before pivotal trials. ImmunoMark’s Stream 2, Biomarkers & Companion Diagnostics, is built around their decisions, and the 1:1 meeting programme lets you book time with them directly.

The people on stage show the level of the room. The 2027 Stream 2 programme opens with a keynote on Clinical Utility of Biomarkers by Espen Walker, Head of Global Medical Diagnostics at AstraZeneca, followed by Companion Diagnostics and the Role of Diagnostics in Precision Medicine from Rafael Carrión Izquierdo of Roche. The speaker panel also includes Oliseyenum Nwose, Global Medical Lead at GSK. In 2026, Yariv Hefez, SVP Head Global Business Franchise Oncology at Merck, moderated the panel “Biomarkers as Market Makers: How Companion Diagnostics Shape Standards of Care”, and Martin Merello, former Head of Precision Medicine at Johnson & Johnson Innovative Medicine, joined the Stream 2 speakers.

55+pre-scheduled 1:1s for title sponsors in 2026

15–25meetings per sponsor in 2026

45–50%senior leadership in the audience

400+target attendees for 2027

Co-development map

The CDx co-development path and where you fit

Pharma teams need different partners at each stage of a companion diagnostic. This map links each stage to the partner type and the London 2027 session where that stage is discussed, which makes ImmunoMark as much a translational oncology conference London CDx teams use as a diagnostics event.

Stage	What pharma needs	Partner type	London 2027 session
Biomarker hypothesis	Evidence that a biomarker predicts benefit; a platform that can measure it reliably	IVD manufacturer, assay developer	Day 1 · Keynote: Clinical Utility of Biomarkers
Clinical trial assay	Validated assay, sample logistics and testing capacity across trial sites	Central lab	Day 2 · Companion Diagnostics Co-development Strategies
Regulatory strategy	A route to approval in each market where the drug will launch	Regulatory consultancy, IVD manufacturer	Day 1 · Regulation of Companion Diagnostics from a Pharma Perspective
Biomarker qualification	Agreement on evidence standards across agencies	Regulatory consultancy	Day 1 · Panel: Regulatory Harmonisation for Biomarker Qualification
Approval	Coordinated submissions across agencies	IVD manufacturer, regulatory consultancy	Day 2 · Panel: Global CDx Approval Pathways – EMA, FDA & MHRA Perspectives
Launch and access	Reimbursement evidence and a lab network that can run the test	IVD manufacturer, central lab	Day 2 · Companion Diagnostics Commercialisation & Reimbursement Strategy

Regulatory backdrop

IVDR and MHRA: the questions your buyers bring

A pharma team launching a targeted oncology drug in Europe now plans for two diagnostic regimes, and often a third.

EU: IVDR

Under the In Vitro Diagnostic Regulation, a companion diagnostic is a class C device. It needs notified body assessment, with the medicines regulator consulted on its suitability for the drug. Partners who have done this before stand out.

Great Britain: MHRA

Great Britain sits outside IVDR, with the MHRA running its own framework for IVDs. Pharma teams need partners who can explain the British route alongside the EU one.

United States: FDA

Global programmes also plan for FDA approval of the CDx alongside the drug. The Day 2 panel puts EMA, FDA and MHRA perspectives side by side.

That three-regime view is why a companion diagnostics conference UK pharma teams find useful needs regulatory depth, not only technology talks. With 40% of delegates travelling from continental Europe, London also works as a companion diagnostics congress Europe-wide pharma teams can reach. For background, see our IVDR companion diagnostics guide.

Packages

Which package fits a CDx partner

For a CDx conference London sponsor, a talk establishes credibility and meetings start the partnership conversation. Choose the mix that matches the size of your deals.

Best fit

Platinum (Stream 2)

A Day 1 talk on the same day as the AstraZeneca keynote, the pharma view on CDx regulation and the Roche session on diagnostics in precision medicine, plus enough meetings to cover several pharma programmes. Client passes let you bring an existing pharma partner.

30-minute Day 1 talk plus Q&A
10 pre-scheduled 1:1 meetings
10 x 6 ft booth
Attendee list a week before
8 + 8 passes

Exclusive 1:1 Meetings

For regulatory and IVDR/MHRA consultancies and central labs whose business is won in a quiet conversation. No booth required.

3, 5, 7 or 10 meetings of 20 minutes
2–4 passes plus drinks reception passes
Wishlist and delegate list

Headline

For an IVD manufacturer that wants to be the diagnostics name for the whole event, with a keynote across both streams on Day 1.

Exclusive to one company
Welcome speech and 30-minute Day 1 keynote, both streams
15 meetings; 10 + 10 passes
20 x 12 ft space; “Powered by” branding
Email campaign to the full pre-qualified database

Gold and Silver add a Day 2 Stream 2 talk at a lower commitment. See all options on the London sponsorship opportunities page, or test the numbers in the ROI calculator below.

Meeting prep

Making a 20-minute CDx meeting count

Twenty minutes is short. The teams that get most from a diagnostics conference London 2027 sponsorship arrive with a short, specific brief.

Bring

One co-development case study with a timeline
Your regulatory track record by market: EU, Great Britain, US
Lab capacity and sample logistics for multi-country trials
A clear answer on who owns the assay after launch

Ask

Where is the programme today, and when is the CDx decision?
Which markets launch first?
Who else in their team signs off the partner choice?
What would a pilot or feasibility study look like?

If you are an EU-based vendor deciding between European events, see biomarker congress Europe 2027 in London. For the wider Stream 2 audience of assay and platform buyers, see the biomarker conference London overview. US CDx partnering at the launch edition is covered on the companion diagnostics conference San Diego page.

Tell us your CDx capabilities and target programmes, and we will suggest how to approach London 2027.

Talk to the sponsorship team

Sponsorship ROI calculator

What could London 2027 be worth to your team?

Pick a package, add your own numbers and see the pipeline it creates. London 2026 sponsors averaged 15 to 25 meetings each, with 70% senior decision-makers in the room.

1. Choose a package

Sponsorship packages

Exclusive 1:1 meeting packages

2. Your numbers

Average first-year deal value

Year-one value of a new pharma or biotech customer

Extra conversations at the event

Booth visits, networking and questions after your talk

Become a real opportunity

Share of conversations worth a proposal

Opportunities you usually win

Your typical close rate

Your total event budget

Sponsorship plus travel and team costs

Estimated return

expected first-year revenue for every £1 of your event budget

Pre-scheduled 1:1 meetings

Qualified conversations

New opportunities

Cost per conversation

Pipeline created

Expected revenue won

Get pricing and the prospectus for this package Or talk to our team about a custom package

Estimates only, based on the numbers you enter. Meetings and inclusions from the London 2027 sponsorship prospectus. 1:1 meetings are pre-scheduled with delegates you choose from the attendee list.

What sponsors said

Feedback from London 2026 sponsors

Here is what sponsors told us at our London 2026 launch edition.

We really liked the focus of the event, the topics, the talks, really good opportunity to engage with people, the support we get from you is really great and we appreciate that very much. Based on our experience we would be very interested in also sponsoring the next annual event.

Project Manager

PromoCell GmbH · Sponsor, London 2026

We are always interested in sponsoring interesting conference, based on this years experience, I guess I will manage to get some budget for the next edition.

BD Manager Europe

Secretech · Sponsor, London 2026

Conversations I have had are very high level, the footfalls been great and the kind of research going on around is really life changing. We will be very interested in sponsoring the second annual.

Research Account Manager

Miltenyi Biotec · Sponsor, London 2026

My experience here at Immunomark 2026 has been really great. We benefit from very good logistical organisation. Networking sessions were excellent and we consider Immunomark a strategic conference for the coming years.

Senior Business Development Director Europe

Rouken Bio · Sponsor, London 2026

We got the occasion to discuss customer projects and understand their needs better and how we can help them.

Epigenomics Applications Specialist

Hologic Diagenode · Sponsor, London 2026

The conference has been great so far with strong interactions at the booth and excellent attendance at our talk. We will definitely think about the next edition.

Biopharma Business Development Manager EMEA

Hologic Diagenode · Sponsor, London 2026

Quality of the talks were really nice and the attendee list had experts from biotech pharma field. It was great meeting everyone and we look forward to positive outcomes.

Business Development Executive

HistologiX · Sponsor, London 2026

The talks have been really interesting so far with a great combination of researchers and clinicians. Moderators encouraged excellent discussions.

Product Specialist

HAWK Biosystems · Sponsor, London 2026

Get the prospectus

Frequently asked questions

Who from pharma is involved in companion diagnostics at ImmunoMark London?

Stream 2 speakers for 2027 include Espen Walker, Head of Global Medical Diagnostics at AstraZeneca, Rafael Carrión Izquierdo of Roche and Oliseyenum Nwose, Global Medical Lead at GSK. The prospectus lists Companion Diagnostics, Precision Medicine, Translational Medicine and Regulatory Affairs among the key departments in the audience.

Does the agenda cover UK and EU regulation for CDx?

Yes. Day 1 includes Regulation of Companion Diagnostics from a Pharma Perspective and a panel on Regulatory Harmonisation for Biomarker Qualification. Day 2 includes a panel on Global CDx Approval Pathways – EMA, FDA & MHRA Perspectives, plus sessions on Companion Diagnostics Commercialisation & Reimbursement Strategy and Companion Diagnostics Co-development Strategies.

We are a regulatory consultancy. Do we need a booth?

No. The Exclusive 1:1 Meetings package gives you 3, 5, 7 or 10 pre-arranged 20-minute meetings, 2–4 passes, drinks reception passes, the wishlist feature and the delegate list with contact details, without exhibition space.

Can we present a CDx co-development case study?

Speaking slots are part of the sponsor packages, in the stream you choose: Platinum includes a 30-minute talk on Day 1, Gold a 30-minute talk on Day 2 pre-lunch, Silver a 15-minute talk on Day 2 post-lunch and Headline a 30-minute Day 1 keynote across both streams. Agree your topic with the sponsorship team.

How many partner meetings can we expect?

Pre-scheduled meetings depend on the package: 15 with Headline, 10 with Platinum, 6 with Gold, and 3 to 10 with the Exclusive 1:1 Meetings package. At London 2026, sponsors averaged 15–25 meetings each and title sponsors received 55+ pre-scheduled 1:1 meetings.

Companion Diagnostics Conference London for CDx Partnering

Get the prospectus and package availability